← All trials
NCT04899427
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 24, 2021
- Primary completion
- Mar 24, 2023
- Completion date
- Oct 24, 2023
- First posted
- May 24, 2021
- Last posted
- May 24, 2021
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Capital Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Peking UniversityCollaborator
- Henan Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Wuhan Renmin UniversityCollaborator
- Hebei Medical UniversityCollaborator
- Shanxi Province Renmin HospitalCollaborator
- Chinese Medical UniversityCollaborator
- Zhengzhou UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.